Core Insights - Neogen reported total second-quarter revenue of $224.7 million, reflecting a core growth of 2.9% and a raised full-year guidance of $845–$855 million in revenue and approximately $175 million in adjusted EBITDA [3][16][17] Financial Performance - Animal Safety revenue was $59.1 million with core revenue growth that was "approximately flat," while Food Safety revenue reached $165.6 million with a core growth of 4.1% [1][2] - Gross margin improved to 47.5%, with adjusted EBITDA at $48.7 million, representing a 21.7% margin, and a sequential improvement of 470 basis points [6][7] - Adjusted net income was $22.6 million, with adjusted EPS of $0.10, compared to $9.4 million and $0.04 in the prior quarter [7] Operational Developments - The company is undergoing a transformation aimed at improving growth and profitability, with a focus on achieving approximately $20 million in annualized cost savings and resolving sample-collection backorders [5][8] - Neogen is on track with the Petrifilm integration and manufacturing transfer project, with production testing showing positive results [10] Leadership and Strategy - New CFO Brian Rigsby and other leadership appointments are expected to enhance execution and innovation, with a shift towards a more process-oriented approach in commercial operations [12] - The company is implementing a "latest best estimate" forecasting process to improve customer-centricity and decision-making [12] Cash Flow and Debt Management - Neogen ended the quarter with $800 million in gross debt and $145.3 million in cash, with free cash flow improving to $7.8 million [13][14] - The company is pursuing a divestiture of its global genomics business, with proceeds aimed at debt reduction [15] Market Outlook - Management expressed a cautious tone for the second half of the fiscal year due to lingering end-market weakness, while emphasizing the importance of building predictability and credibility with investors [4][16][17] - The company anticipates a modest increase in fourth-quarter revenue compared to the third quarter, with expectations for continued positive free cash flow [16][17]

Financial Data and Key Metrics Changes - Total Q2 revenues were $224.7 million, increasing 2.9% on a core basis, with foreign currency contributing 0.9% and divestitures and discontinued products being a headwind of 6.6% [12][19] - Adjusted EBITDA was $48.7 million, representing a margin of 21.7%, an improvement of 470 basis points from Q1 [19] - Gross margin in Q2 was 47.5%, a sequential improvement of 210 basis points from Q1, primarily due to volume and lower tariff costs [18] Business Line Data and Key Metrics Changes - Food safety segment revenues were $165.6 million, with core revenue growth of 4.1%, driven by strong growth in indicator testing and culture media product categories [13] - Animal safety segment revenues were $59.1 million, with core revenue growth approximately flat compared to the prior year, although biosecurity products saw solid growth [15] - The global genomics business had core revenue growth accelerate to 6%, with solid growth in the bovine market [16] Market Data and Key Metrics Changes - Core revenue growth in Q2 was led by the LATAM region, up high single digits, while the U.S. and Canada region had mid-single-digit growth [17] - The APAC region saw low single-digit core growth, while the EMEA region experienced a low single-digit decline [17] Company Strategy and Development Direction - The company is focused on stabilizing and strengthening its core business, with a clear emphasis on improved top-line growth and profitability [4] - A rigorous process-oriented approach to commercial excellence is being implemented, emphasizing strong operational planning and data-driven decisions [5] - The leadership team has been strengthened with experienced operators to drive transformation and operational efficiency [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in overcoming recent macroeconomic and execution-related headwinds, with a belief that challenges are solvable or transitory [4][10] - The company raised its full-year guidance for fiscal 2026, expecting revenue in the range of $845 million to $855 million and adjusted EBITDA of approximately $175 million [20] Other Important Information - The company is in the process of divesting its global genomics business, which is expected to simplify operations and enhance margins [22][23] - The integration of Petrifilm is on track for the Q2 of fiscal 2027, with positive progress in production testing and product validation [9][56] Q&A Session Summary Question: Can you discuss the new management team and how long it will take for them to gel? - Management highlighted the recruitment of top-tier talent and emphasized the importance of experienced leaders in diagnostics and life sciences to drive operational excellence [30][32] Question: What was the headwind to margins from sample handling? - Management acknowledged challenges in sample collection but indicated improvements are expected in the second half of the year, with a focus on profitability [34][36] Question: Why hasn't the implied H2 growth or margin been higher? - Management stated that a conservative approach is being taken due to lingering macroeconomic weaknesses and the need for the new team to settle in [41][42] Question: Were there any one-time revenue tailwinds in the quarter? - Management noted a $2 million insecticide tailwind in Q2 but indicated that it was the only significant one-time factor [45] Question: What changes in the commercial organization have contributed to the strong quarter? - Management emphasized a focus on the basics, driving simplicity, and implementing a weekly forecasting process to enhance predictability [52][54] Question: How is the Petrifilm manufacturing process progressing? - Management expressed confidence in the Petrifilm project, stating that production testing is going well and the timeline remains on track [56]

Financial Data and Key Metrics Changes - Total second quarter revenues were $224.7 million, increasing 2.9% on a core basis, with foreign currency contributing 0.9% and divestitures and discontinued products impacting by 6.6% [12][19] - Adjusted EBITDA was $48.7 million, representing a margin of 21.7%, an improvement of 470 basis points from the first quarter [19] - Gross margin in the second quarter was 47.5%, a sequential improvement of 210 basis points from the first quarter, primarily due to volume and lower tariff costs [18] Business Line Data and Key Metrics Changes - Food safety segment revenues were $165.6 million, with core revenue growth of 4.1%, driven by strong growth in indicator testing and culture media product categories [13] - Animal safety segment revenues were $59.1 million, with core revenue growth approximately flat compared to the prior year quarter, despite solid growth in biosecurity products [15] - Global genomics business had core revenue growth accelerate to 6%, with solid growth in the bovine market [16] Market Data and Key Metrics Changes - Core revenue growth in the Latham region was high single digits, while the U.S. and Canada region had mid-single-digit growth [17] - APAC region saw low single-digit core growth, led by pathogen detection products, while EMEA region had a low single-digit core growth decline [17] Company Strategy and Development Direction - The company is focused on improving top-line growth and profitability, with a transformation strategy centered on stabilizing and strengthening its core [4] - A rigorous process-oriented approach to commercial excellence is being implemented, emphasizing strong operational planning and data-driven decisions [5] - The leadership team has been strengthened with experienced operators to drive growth and innovation [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in overcoming macroeconomic and execution-related headwinds, with a belief that challenges are solvable or transitory [4] - The company raised its full-year guidance for fiscal 2026, expecting revenue in the range of $845 million-$855 million and adjusted EBITDA of approximately $175 million [20] - Management acknowledged the importance of building credibility with investors and maintaining a conservative approach to guidance amid lingering market weaknesses [42] Other Important Information - The company is in the process of divesting its global genomics business, which is expected to simplify operations and enhance incremental margins [22][23] - The integration of Petrifilm is on track for the second quarter of fiscal 2027, with positive progress in production testing and product validation [9][56] Q&A Session Summary Question: Can you discuss the new management team and their integration? - Management highlighted the recruitment of top-tier talent with experience in diagnostics and life sciences, emphasizing the importance of operational excellence and alignment on priorities [30][32] Question: What are the headwinds to margins from sample handling? - Management acknowledged challenges in sample collection but expressed optimism for profitability improvements in the second half of the year [34][36] Question: Why is the implied H2 growth or margin not higher? - Management indicated a prudent approach to guidance, focusing on sustainable performance and the settling in of the new team [41][42] Question: Were there any one-time revenue tailwinds in the quarter? - Management noted a $2 million insecticide tailwind in the animal safety segment as the only significant one-time factor [45] Question: What changes in the commercial organization have contributed to recent success? - Management emphasized a focus on basics, driving simplicity, and implementing a weekly forecasting process to enhance predictability [51][52]

Financial Data and Key Metrics Changes - Total second quarter revenues reached $224.7 million, reflecting a 2.9% increase on a core basis, with foreign currency contributing 0.9% and divestitures and discontinued products impacting by 6.6% [11][12] - Adjusted EBITDA was $48.7 million, representing a margin of 21.7%, an improvement of 470 basis points from the first quarter [17] - Adjusted net income and adjusted earnings per share were $22.6 million and $0.10, respectively, compared to $9.4 million and $0.04 in the prior quarter [18] Business Line Data and Key Metrics Changes - Food safety segment revenues were $165.6 million, with core revenue growth of 4.1%, driven by strong performance in indicator testing and culture media product categories [12] - Animal safety segment revenues were $59.1 million, with core revenue growth approximately flat compared to the prior year, although biosecurity products saw solid growth [13] - The global genomics business experienced core revenue growth of 6%, with strong performance in the bovine market [14] Market Data and Key Metrics Changes - Core revenue growth in the Latham region was high single digits, while the U.S. and Canada region saw mid-single-digit growth [15] - The APAC region experienced low single-digit core growth, led by pathogen detection products, while the EMEA region had a low single-digit decline [16] - Gross margin improved to 47.5%, a sequential increase of 210 basis points, primarily due to volume and lower tariff costs [17] Company Strategy and Development Direction - The company is focused on stabilizing and strengthening its core business, with a transformation aimed at improving top-line growth and profitability [4] - A rigorous process-oriented approach to commercial excellence is being implemented, emphasizing operational planning and data-driven decisions [5] - The leadership team has been strengthened with experienced operators to drive growth and innovation [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in overcoming macroeconomic and execution-related headwinds, with a positive outlook for the year [4][10] - The company raised its full-year guidance for fiscal 2026, expecting revenues between $845 million and $855 million and adjusted EBITDA of approximately $175 million [19] - Management acknowledged the challenges in the operating environment but believes they are solvable or transitory [10] Other Important Information - The company is in the process of divesting its global genomics business, which is expected to simplify operations and enhance margins [20][21] - Cost structure improvements implemented in the second quarter are expected to deliver approximately $20 million in annualized savings [4] Q&A Session Summary Question: Discussion on the new management team and its impact - Management highlighted the recruitment of top-tier talent with experience in diagnostics and life sciences, emphasizing the importance of operational excellence and alignment within the team [28][29] Question: Concerns about growth and margin expectations for H2 - Management indicated a conservative approach to guidance, focusing on sustainable performance and the need for the new team to settle in [38][39] Question: One-time revenue tailwinds in the quarter - A $2 million insecticide tailwind was noted in the animal safety segment, but no other significant one-time revenues were reported [42] Question: Changes in the commercial organization leading to improved forecasts - The focus on basics and driving simplicity, along with a new weekly forecasting process, has improved organizational alignment and performance [48][49] Question: Confidence in the Petrifilm manufacturing process - Management expressed confidence in the Petrifilm project, stating that production testing is progressing well and remains on track for the November 2027 timeline [51][52]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Financial Performance - Neogen's core revenue increased by 2.9% year-over-year[9] - Adjusted EBITDA margins improved sequentially by 470 bps to 21.7%[9] - Q2 FY26 revenue reached $224.7 million[19] compared to $209.2 million in Q1 FY26 and $231.3 million in Q2 FY25[19] - Adjusted EBITDA for Q2 FY26 was $48.7 million with a margin of 21.7%[20], compared to $35.5 million with a margin of 17.0% in Q1 FY26 and $51.4 million with a margin of 22.2% in Q2 FY25[20] - Adjusted Net Income for Q2 FY26 was $22.6 million[21], or $0.10 per share[21], compared to $9.4 million[21], or $0.04 per share in Q1 FY26[21], and $24.4 million[21], or $0.11 per share in Q2 FY25[21] Segment Performance - Food Safety core revenue grew by 4.1%[23] - Animal Safety core revenue grew by 0.1%[23] Balance Sheet and Capital Allocation - Net debt is $655 million[26] - Debt is 68% fixed[26] - Q2 Free Cash Flow improved by $21 million compared to Q1[28] FY2026 Outlook - Total revenue is projected to be between $845 million and $855 million[32] - Adjusted EBITDA is expected to be approximately $175 million[32] - Capital expenditures are estimated at around $50 million[32] - The effective tax rate is projected at 21%[32]

Financial Performance - Revenues for the second quarter were $224.7 million, a decrease of 2.8% compared to $231.3 million in the prior year, while core revenue increased by 2.9%[4] - Net loss for the second quarter was $15.9 million, or $(0.07) per diluted share, compared to a net loss of $456.3 million, or $(2.10) per diluted share, in the prior-year period[5] - Adjusted EBITDA was $48.7 million, representing an Adjusted EBITDA margin of 21.7%, compared to $51.4 million and a margin of 22.2% in the prior-year period[7] - Adjusted Net Income for the second quarter was $22.6 million, compared to $24.4 million in the prior-year period[5] - For the three months ended November 30, 2025, the net loss was $15,924,000 compared to a net loss of $456,282,000 for the same period in 2024[34] - Adjusted net income for the six months ended November 30, 2025, was $32,063,000, down from $38,730,000 in 2024, reflecting a decrease of 17.3%[34] - Adjusted earnings per share for the three months ended November 30, 2025, was $0.10, a decrease from $0.11 in the same period of 2024[34] Segment Performance - Food Safety segment revenues were $165.6 million, an increase of 0.8% year-over-year, with a 4.1% core revenue increase[9] - Animal Safety segment revenues were $59.1 million, a decrease of 11.8% year-over-year, with a 0.1% core revenue increase[10] - Food Safety segment revenue for Q2 FY26 was $165,554,000, showing a growth of 0.8% compared to $164,238,000 in Q2 FY25[37] - Animal Safety segment revenue decreased by 11.8% to $59,137,000 in Q2 FY26 from $67,020,000 in Q2 FY25[37] - Total revenue for Neogen in Q2 FY26 was $224,691,000, down 2.8% from $231,258,000 in Q2 FY25[37] Outlook and Strategic Initiatives - The company is raising its full-year revenue outlook for fiscal year 2026 to a range of $845 million to $855 million[13] - The company plans to continue focusing on transformation initiatives and related costs to improve operational efficiency[31] - The company has strengthened its leadership team with key additions to its commercial organization to support strategic transformation initiatives[3] Balance Sheet and Cash Flow - As of November 30, 2025, the company had total cash and cash equivalents of $145.3 million and total outstanding debt of $800.0 million[12] - Cash and cash equivalents increased to $145,340 as of November 30, 2025, from $129,004 at the beginning of the year[24] - Total assets decreased to $3,359,953 as of November 30, 2025, down from $3,443,836 as of May 31, 2025[22] - Total liabilities decreased to $1,255,465 as of November 30, 2025, compared to $1,372,582 as of May 31, 2025[22] - The current portion of debt was eliminated, reducing current liabilities to $147,050 as of November 30, 2025, from $174,011[22] Impairments and Other Adjustments - The company incurred a goodwill impairment of $461,390 in the prior year, which significantly impacted net income[30] - The company reported a goodwill impairment of $461,390,000 for the six months ended November 30, 2024[34] - The company incurred $22,369,000 in amortization of acquisition-related intangibles for the three months ended November 30, 2025[34] - The estimated tax effect of adjustments for the three months ended November 30, 2025, was $(9,756,000)[34] - The company experienced a foreign currency transaction loss of $180,000 for the three months ended November 30, 2025[34] - The company reported a gain on the sale of business amounting to $76,390 during the six months ended November 30, 2025[30]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

分组1 - Neogen Corporation is set to release its first-quarter earnings results on January 8, 2025, with expected earnings of 7 cents per share, a decrease from 11 cents per share in the same period last year [1] - The consensus estimate for Neogen's quarterly revenue is $208.38 million, which is a decline from $231.26 million a year earlier [1] - On January 5, Neogen announced the appointments of Joe Freels as Senior Vice President and Chief Commercial Officer, and Dr. Tammi Ranalli as Senior Vice President and General Manager, Global Food Safety [2] 分组2 - Neogen's shares rose by 2.1% to close at $7.41 following the announcement of new executive appointments [2] - Analyst Robert Labick upgraded Neogen's stock from Market Perform to Market Outperform with a price target of $10 on December 10, 2025 [4] - Piper Sandler analyst David Westenberg maintained a Neutral rating and increased the price target from $5 to $6.5 on October 16, 2025 [4] - William Blair analyst Brandon Vazquez downgraded the stock from Outperform to Market Perform on July 29, 2025 [4] - Guggenheim analyst Subbu Nambi maintained a Buy rating and decreased the price target from $13 to $10 on June 30, 2025 [4]

Group 1 - Neogen Corporation is set to release its first-quarter earnings results on January 8, 2025, with expected earnings of 7 cents per share, a decrease from 11 cents per share in the same period last year [1] - The consensus estimate for Neogen's quarterly revenue is $208.38 million, down from $231.26 million a year earlier [1] Group 2 - On January 5, Neogen announced the appointments of Joe Freels as Senior Vice President and Chief Commercial Officer, and Dr. Tammi Ranalli as Senior Vice President and General Manager, Global Food Safety [2] - Following the announcement, Neogen's shares rose by 2.1% to close at $7.41 [2] Group 3 - CJS Securities analyst Robert Labick upgraded Neogen's stock from Market Perform to Market Outperform with a price target of $10 [4] - Piper Sandler analyst David Westenberg maintained a Neutral rating and increased the price target from $5 to $6.5 [4] - William Blair analyst Brandon Vazquez downgraded the stock from Outperform to Market Perform [4] - Guggenheim analyst Subbu Nambi maintained a Buy rating and decreased the price target from $13 to $10 [4]